首页 > 市场调查报告书 > 製药

疼痛

市场调查报告书

商品编码

1593459

偏头痛药物市场规模、份额、成长分析（按治疗层级、途径途径和地区）- 产业预测，2024-2031 年

Migraine Drugs Market Size, Share, Growth Analysis, By Treatment Class, By Therapeutic Class, By Route of Administration, By Region - Industry Forecast 2024-2031.

出版日期: 2024年11月14日 | 出版商:

SkyQuest | 英文 207 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年，偏头痛治疗药物的全球市场规模为38.9亿美元，从2023年的45亿美元成长到2031年的172.5亿美元，预测期（2024-2031）预计复合年增长率为18.0%。

偏头痛药物市场主要集中在缓解或预防偏头痛症状的药物，分为急性治疗药物和预防药物。急性治疗药物旨在即时缓解偏头痛发作，而预防药物则旨在减少偏头痛发作的频率和严重程度。市场成长的主要驱动力包括人们对有效预防方法的认识提高、诊断能力的进步以及创新药物的推出。然而，挑战仍然存在，包括新治疗方法的高成本和潜在的副作用，让医疗保健专业人员和患者望而却步。儘管存在这些障碍，在药物开发的进步、向个人化医疗的转变以及新兴市场的巨大机会的推动下，偏头痛治疗市场在未来几年仍将大幅扩张。相关人员寻求解决未满足的医疗需求并改善偏头痛管理中的患者治疗效果。

北美洲
- 美国
- 加拿大
欧洲
- 英国
- 德国
- 西班牙
- 法国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东/非洲

竞争资讯

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2023）
主要企业简介
- 公司简介
- 产品系列分析
- 按细分市场分類的份额分析
- 收益与前一年同期比较（2021-2023）

主要企业简介

Pfizer
GlaxoSmithKline
Allergan
Amgen
Eli Lilly
Teva Pharma
Biohaven Pharma
Johnson & Johnson
Valeant Pharma
AbbVie Inc
Eli Lilly and Company
Novartis International AG
Novartis International AG
Biohaven Pharmaceuticals
Boehringer Ingelheim
Zynerba Pharmaceuticals
Teva Pharmaceutical
Hoffmann-La Roche Ltd
Amgen
AstraZeneca

结论和建议

简介目录

Product Code: SQMIG35I2350

Global Migraine Drugs Market size was valued at USD 3.89 Billion in 2022 and is poised to grow from USD 4.50 Billion in 2023 to USD 17.25 Billion by 2031, growing at a CAGR of 18.0% in the forecast period (2024-2031).

The migraine drug market is primarily focused on medications designed to alleviate or prevent migraine symptoms, categorized into acute and preventive medications. Acute treatments target immediate relief during migraine attacks, while preventive medications work to reduce the frequency and severity of these episodes. Key drivers of market growth include increasing awareness surrounding effective preventive options, advancements in diagnostic capabilities, and the introduction of innovative pharmaceuticals. However, challenges persist, such as the high cost of new therapies and the potential side effects that may lead to hesitancy among both healthcare providers and patients. Despite these obstacles, the migraine drug market is poised for significant expansion in the coming years, fueled by advancements in drug development, a shift toward personalized medicine, and promising opportunities within emerging markets. This combination of factors suggests a robust growth trajectory, as stakeholders seek to address unmet medical needs and improve patient outcomes in migraine management.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Migraine Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Migraine Drugs Market Segmental Analysis

Global Migraine Drugs Market is segmented by Treatment, Therapeutic Class, Route of Administration, Age Group, Availability and region. Based on Treatment, the market is segmented into Acute, Preventive. Based on Therapeutic Class, the market is segmented into CGRP monoclonal antibodies, CGRP small molecule antagonists, Acetylcholine inhibitors/ neurotoxins, Triptans, Ditans, Ergot alkaloids, NSAIDs, Others. Based on Route of Administration, the market is segmented into Oral, Injectable, Others. Based on Age Group, the market is segmented into Pediatric, Adult, Geriatric. Based on Availability, the market is segmented into Prescription Drugs, Over-the-Counter (OTC) Drugs. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Migraine Drugs Market

The Global Migraine Drugs market is significantly driven by the introduction of novel drug categories, such as CGRP gepants and inhibitors, which mark a substantial advancement in migraine management. These innovative treatments utilize targeted mechanisms, demonstrating superior efficacy in reducing both the severity and frequency of migraine attacks. As research into migraine pathophysiology continues to advance, the market is witnessing an influx of modernized therapies, including personalized treatment options informed by genetic and molecular insights. This dynamic landscape of innovative therapies not only enhances patient outcomes but also propels market growth by attracting investment and fostering a competitive environment among pharmaceutical companies.

Restraints in the Global Migraine Drugs Market

The global migraine drugs market faces significant restraints due to the variability in drug efficacy among patients, leading to inconsistent treatment outcomes and dissatisfaction. This discrepancy can prompt patients to seek alternative therapies, thereby limiting the uptake of conventional migraine medications. Furthermore, novel migraine treatments, while often effective, may present side effects that adversely affect patients' quality of life, potentially resulting in treatment discontinuation or the need for additional medications to manage these adverse effects. Such factors contribute to a hesitant patient base, ultimately hindering the overall growth and development of the migraine drug market.

Market Trends of the Global Migraine Drugs Market

The Global Migraine Drugs market is experiencing a significant trend towards the adoption of CGRP inhibitors, which have quickly emerged as preferred treatment options for migraine prophylaxis. Drugs like Aimovig, Emgality, and Ajovy have demonstrated remarkable efficacy in reducing both the frequency and severity of migraines, capturing the attention of healthcare providers and patients alike. Their convenient dosing options-either quarterly or monthly-add to their appeal, especially for chronic migraine sufferers seeking sustained relief. This shift towards targeted therapies indicates a broader movement within the pharmaceutical industry to prioritize personalized and effective migraine management solutions, thereby reshaping market dynamics and growth potential.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Driver & Opportunities
- Restraints & Challenges
Porters Analysis & Impact
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Technological Advancement
Regulatory Landscape
Patent Analysis
Value Chain Analysis
Case Study Analysis
PESTEL Analysis
Macro-Economic Indicators
Trade Analysis
Market Attractiveness Index
Supply Chain Analysis
Pricing Analysis

Global Migraine Drugs Market Size by Treatment & CAGR (2024-2031)

Acute
Preventive

Global Migraine Drugs Market Size by Therapeutic Class & CAGR (2024-2031)

CGRP monoclonal antibodies
CGRP small molecule antagonists
Acetylcholine inhibitors/ neurotoxins
Triptans
Ditans
Ergot alkaloids
NSAIDs
Others

Global Migraine Drugs Market Size by Route of Administration & CAGR (2024-2031)

Oral
Injectable
Others

Global Migraine Drugs Market Size by Age Group & CAGR (2024-2031)

Pediatric
Adult
Geriatric

Global Migraine Drugs Market Size by Availability & CAGR (2024-2031)

Prescription Drugs
Over-the-Counter (OTC) Drugs

Global Migraine Drugs Market Size & CAGR (2024-2031)

North America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- US
- Canada
Europe, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
Latin America, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- Brazil
- Rest of Latin America
Middle East & Africa, (Treatment, Therapeutic Class, Route of Administration, Age Group, Availability)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2023
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biohaven Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Valeant Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis International AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biohaven Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zynerba Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments